• #1212567
  • AbbVie US LLC #00074501501

SKYRIZI® Risankizumab-rzaa 60 mg / mL Injection Single-Dose Vial 10 mL

SKYRIZI, SDV 600MG/10ML D/S

Features
  • SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
  • SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults
  • SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults
  • More …
Container Type
Single-Dose Prefilled Cartridge Single-Dose Vial
Strength
60 mg / mL 150 mg / mL
Type
Intravenous Subcutaneous
Volume
1.2 mL 2.4 mL 10 mL
  Log In to Order
or

Product Specifications


Features
  • SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
  • SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults
  • SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults
  • 600 mg/10 mL (60 mg/mL) single-dose vial

Professionals Also Viewed